Breaking News Instant updates and real-time market news.

OREX

Orexigen

$2.04

-0.01 (-0.49%)

, TEVA

Teva

$14.96

-0.1948 (-1.29%)

14:42
10/13/17
10/13
14:42
10/13/17
14:42

Orexigen: Court issues ruling in favor of company in Actavis litigation

Orexigen Therapeutics (OREX) announced that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories FL, Inc. for three patents for Contrave with exclusivity through 2030. Actavis is owned by Teva (TEVA). "Orexigen's intent was to vigorously defend our intellectual property and we are very pleased with the Court's decision upholding the validity of all of the patents involved in the case," said Michael Narachi, President and CEO of Orexigen. "The Court's positive decision allows Orexigen to continue to fulfill its mission to provide innovative medicine to treat patients who are overweight or struggling with obesity." Narachi added, "As we progress on our path to profitability by 2019, we expect that exclusivity through 2030 will provide many valuable years of growing profitability for Contrave."

OREX

Orexigen

$2.04

-0.01 (-0.49%)

TEVA

Teva

$14.96

-0.1948 (-1.29%)

  • 17

    Oct

  • 02

    Nov

OREX Orexigen
$2.04

-0.01 (-0.49%)

TEVA Teva
$14.96

-0.1948 (-1.29%)

10/04/17
10/04/17
NO CHANGE

BTIG keeps price target on Teva unchanged despite Mylan news
Mylan analyst Timothy Chiang maintained his previous $24 price target on Teva (TEVA) despite the news that Mylan (MYL) had received approval to market the generic version of Copaxone. The analyst says that "the bulk of the downside" from the launch of generic versions of Copaxone was reflected in Teva's stock before the Mylan news was announced. He remains upbeat on Teva's new CEO and keeps a Buy rating on the shares.
10/04/17
BTIG
10/04/17
NO CHANGE
BTIG
Mylan generic Copaxone sales could reach $450M in first year, says BTIG
BTIG analyst Timothy Chiang estimates that Mylan (MYL) could obtain up to $450M of sales from its generic version of Teva's (TEVA) Copaxone in the first year in which it is marketed. The analyst believes that the approval "validates" the company's status as a "premier" generic drugmaker and shows that one can never assume that it will lose a battle over generic drug rights. The analyst raised his price target on the shares to $45 from $42 and keeps a Buy rating on the stock.
10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
10/13/17
WELS
10/13/17
NO CHANGE
Target $276
WELS
Outperform
Allergan settlement leaves three Restasis challengers, say Wells Fargo
Wells Fargo analyst David Maris says three Restasis generic challengers remain after Allergan (AGN) reached a settlement with InnoPharma. The settlement, which allows InnoPharma to launch a generic Restasis in the U.S. beginning February 24, 2024, or six months before the expiration of Allergan's patents, points to the complexity of Restasis and the difficulty of getting a generic version approved, Maris tells investors in a research note. InnoPharma was one of four included in a consolidated lawsuit against Allergan, with Teva (TEVA), Mylan (MYL) and Akorn (AKRX) remaining, Maris points out. He's encouraged that the settlement date reached with InnoPharma is close to the expiration date of the patents. The analyst keeps an Outperform rating on Allergan with a $276 price target.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$95.18

1.73 (1.85%)

13:10
10/23/17
10/23
13:10
10/23/17
13:10
Options
Texas Instruments calls active as shares see relative strength ahead of earnings »

Texas Instruments calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

EEFT

Euronet

$98.71

1.93 (1.99%)

13:09
10/23/17
10/23
13:09
10/23/17
13:09
Conference/Events
Euronet management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Dec

NVS

Novartis

$86.19

0.45 (0.52%)

, MCD

McDonald's

$164.22

-2.08 (-1.25%)

13:06
10/23/17
10/23
13:06
10/23/17
13:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$86.19

0.45 (0.52%)

MCD

McDonald's

$164.22

-2.08 (-1.25%)

MMM

3M

$222.12

0.8 (0.36%)

UTX

United Technologies

$120.63

-0.3 (-0.25%)

LLY

Eli Lilly

$87.68

0.45 (0.52%)

LMT

Lockheed Martin

$320.44

0.44 (0.14%)

CAT

Caterpillar

$132.06

0.7 (0.53%)

BIIB

Biogen

$338.10

-4.32 (-1.26%)

GM

General Motors

$45.37

-0.2389 (-0.52%)

SHW

Sherwin-Williams

$389.65

-0.055 (-0.01%)

INFY

Infosys

$14.90

0.34 (2.34%)

GLW

Corning

$30.36

0.295 (0.98%)

PCAR

Paccar

$74.92

1.15 (1.56%)

SWK

Stanley Black & Decker

$159.75

-0.37 (-0.23%)

FITB

Fifth Third

$28.60

0.32 (1.13%)

CNC

Centene

$97.59

1.09 (1.13%)

WAT

Waters

$188.63

0.49 (0.26%)

IPG

Interpublic Group

$20.62

-0.2641 (-1.26%)

WAB

Wabtec

$76.28

-0.59 (-0.77%)

HUBB

Hubbell

$121.43

-1.6355 (-1.33%)

JBLU

JetBlue

$20.35

0.01 (0.05%)

PII

Polaris Industries

$106.55

0.09 (0.08%)

GPK

Graphic Packaging

$14.30

0.02 (0.14%)

R

Ryder

$82.98

-0.67 (-0.80%)

CVLT

Commvault

$58.55

0.5 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 07

    Dec

  • 17

    May

WHR

Whirlpool

$182.85

0.39 (0.21%)

, ARNC

Arconic

$25.05

-2.12 (-7.80%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Earnings
Notable companies reporting after market close »

Notable companies…

WHR

Whirlpool

$182.85

0.39 (0.21%)

ARNC

Arconic

$25.05

-2.12 (-7.80%)

ZION

Zions Bancorp

$46.76

0.71 (1.54%)

CR

Crane

$84.02

-0.09 (-0.11%)

OI

Owens-Illinois

$25.35

-0.24 (-0.94%)

RMBS

Rambus

$13.70

0.12 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 14

    Nov

  • 07

    Dec

COG

Cabot Oil & Gas

$25.39

-0.14 (-0.55%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Options
Cabot Oil & Gas call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

13:05
10/23/17
10/23
13:05
10/23/17
13:05
General news
Treasury Action: the markets are quiet as a wait and see stance prevails »

Treasury Action: the…

NKE

Nike

$53.79

0.73 (1.38%)

12:55
10/23/17
10/23
12:55
10/23/17
12:55
Options
Nike put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ADP

ADP

$115.93

1.31 (1.14%)

12:54
10/23/17
10/23
12:54
10/23/17
12:54
Hot Stocks
ADP 'strongly disagrees' with Glass Lewis' recommendation on director election »

ADP issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

UTX

United Technologies

$120.73

-0.205 (-0.17%)

12:46
10/23/17
10/23
12:46
10/23/17
12:46
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend ahead of news »

Shares have been trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FCX

Freeport McMoRan

$14.78

-0.049 (-0.33%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AGN

Allergan

$189.61

1.33 (0.71%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Periodicals
Allergan has weak balance sheet after large buybacks, WSJ's Grant says »

Allergan squandered the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

SSYS

Stratasys

$23.21

2.26 (10.79%)

12:37
10/23/17
10/23
12:37
10/23/17
12:37
Hot Stocks
Stratasys announces NYU study on treating kidney issues with 3D technology »

Stratasys announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

TAL

TAL Education

$34.05

-0.865 (-2.48%)

12:35
10/23/17
10/23
12:35
10/23/17
12:35
Options
Tal Education Group put volume heavy and directionally bearish »

Bearish flow noted in Tal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

LGL

LGL Group

$5.66

0.1 (1.80%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Hot Stocks
LGL Group reports extension of rights offering expiration to November 13 »

The LGL Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBW

Build-A-Bear

$8.15

-0.1 (-1.21%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Conference/Events
Build-A-Bear management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

SYBX

Synlogic

$15.01

-1.46 (-8.86%)

12:28
10/23/17
10/23
12:28
10/23/17
12:28
Conference/Events
Synlogic management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ROIC

Retail Opportunity

$18.76

-0.3 (-1.57%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Conference/Events
Retail Opportunity management to meet with Jefferies »

Meetings to be held n…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

MCD

McDonald's

$164.42

-1.88 (-1.13%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Technical Analysis
Technical Earnings Preview: McDonald's testing support ahead of earnings »

Price has been within a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

XOM

Exxon Mobil

$83.21

0.1 (0.12%)

12:20
10/23/17
10/23
12:20
10/23/17
12:20
Options
11.7K Exxon Mobile Jan 82.5 - Mar 87.5 call spreads bought for $1.40 »

11.7K Exxon Mobile Jan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

$NSD

NASDAQ Market Internals

12:17
10/23/17
10/23
12:17
10/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
10/23/17
10/23
12:16
10/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
10/23/17
10/23
12:15
10/23/17
12:15
General news
Treasury Option Action: some "call fly" demand »

Treasury Option Action:…

SAGE

Sage Therapeutics

$63.50

0.58 (0.92%)

12:10
10/23/17
10/23
12:10
10/23/17
12:10
Options
Sizable ratio spread in Sage Therapeutics »

Sizable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$35.00

-0.25 (-0.71%)

12:08
10/23/17
10/23
12:08
10/23/17
12:08
Periodicals
Volkswagen receives approval from U.S regulators for SUV fix, Reuters says »

U.S and California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBS

Rambus

$13.70

0.12 (0.88%)

12:05
10/23/17
10/23
12:05
10/23/17
12:05
Technical Analysis
Technical Earnings Preview: Rambus in bullish price channel ahead of news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.